Intravenous vs. intraprostatic administration of N-methyl-N-nitrosourea to induce prostate cancer in rats.
To develop an improved model of human prostate cancer, 16-wk-old Wistar rats were treated orally for 18 days with the antiandrogen, flutamide (50 mg/kg body weight [BW]/day), followed by 3 days of s.c. testosterone (100 mg/kg BW). There were the only treatments the control animals received (Group 1, n = 10). On the day after the third testosterone injection, N-methyl-N-nitorsourea (MNU) was administered via the tail vein at a dose of 50 mg/kg BW (Groups 2, n = 40 and 3, n = 20); in some rats, a second dose was delivered by the same route 22 wk later (Group 3). A smaller dose of MNU (15 mg/kg BW) was administered intraprostatically (Group 4, n = 20) to a fourth group. In Groups 2, 3, and 4, silastic capsules containing testosterone were implanted s.c. approximately every 6 wk beginning 1 wk post-MNU. Accessory sex gland tumors arose in MNU-treated rats in Group 2 (12/40, 30%). Group 3 (8/20, 40%), and Group 4 (8/20, 40%); 90% were macroscopic (25/28). There were no neoplasms in these organs in the control rats (Group 1, 0/10). These accessory sex gland neoplasms were adenocarcinomas or undifferentiated carcinomas which appeared to be derived from the prostate based on location and histological characteristics, although the size and spread of some of the tumors precluded definitive localization of the tissue of origin. The incidence of these neoplasms was similar in rats given a single dose of MNU intraprostatically or two doses of MNU i.v., but the animals treated intraprostatically maintained higher body weights and developed fewer extraneous tumors. The average (+/- SD) latent period for clinical or postmortem detection of prostate neoplasia after MNU was shortest in the rats given two i.v. doses (39 +/- 3 wk) compared with the single i.v. dose (45 +/- 6 wk) or an intraprostatic dose (56 +/- 7 wk). In 57% of the cases (16/28), the prostate tumors metastasized to distant sites. An activating point mutation was detected in codon 12 of the Ki-ras oncogene in the MNU-induced primary prostate tumors (8/10 examined), and metastases arising from these prostate tumors (2/3) but was absent in normal prostate tissue (0/6). This study demonstrates that two systemic doses of MNU increase the incidence and decrease the latency of prostate neoplasms compared with a single dose, and that a single dose of MNU injected intraprostatically induces prostate adenocarcinoma without many of the other tumors and weight loss typically found after i.v. administration.
Schleicher
R L
RL
Medical Research Service, Veterans Affairs Medical Center (Atlanta), Decatur, GA 30033, USA.
Fallon
M T
MT
Austin
G E
GE
Zheng
M
M
Zhang
M
M
Dillehay
D L
DL
Collins
D C
DC
D000230:Adenocarcinoma / Q000139:chemically induced* / Q000556:secondary; D000818:Animals; D001483:Base Sequence; D002273:Carcinogens / Q000008:administration & dosage*; D003062:Codon; D004247:DNA / Q000032:analysis; D004252:DNA Mutational Analysis; D004305:Dose-Response Relationship, Drug; D011905:Genes, ras; D015552:Injections, Intralesional; D007275:Injections, Intravenous; D008297:Male; D008770:Methylnitrosourea / Q000008:administration & dosage*; D008969:Molecular Sequence Data; D016133:Polymerase Chain Reaction; D011471:Prostatic Neoplasms / Q000139:chemically induced* / Q000473:pathology; D051381:Rats; D017208:Rats, Wistar
D002273:Carcinogens; D003062:Codon; D008770:Methylnitrosourea; D004247:DNA